A Phase 1/2 interventional study of Metfomin in Mild Cognitive Impairment, Overweight or Obesity and Elderly, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Fudan University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing metformin in Cognitive Dysfunction — 3 open to participants now, 4 under way, 2 of them phase 3. Metformin · Cognitive Dysfunction.
Among the 10 studies testing metformin in Cognitive Dysfunction, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 10th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →3 of the 10 studies testing metformin in Cognitive Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Donald Mabbott · Sites in Australia, Canada
Ages 7–21
Beni-Suef University · Sites in Egypt
Ages 45–60
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 84 across the 10 interventional studies. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
Fudan University has 4 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Cognitive Dysfunction that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05230758Phase 3Donald MabbottEffect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing metformin in Cognitive Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The prevalence of cognitive impairment in elderly obese patients is high, and the burden on families and society is heavy. Early intervention for mild cognitive impairment (MCI) is of great value. Central nervous system insulin resistance plays a role in the pathogenesis of cognitive impairment, and functional magnetic resonance imaging(fMRI) can evaluate cognitive impairment by observing central insulin resistance. Some large database studies of Type 2 Diabetes show that metformin is related to reducing the risk of dementia, but some studies have different conclusions, and there is few related study in elderly obese patients. The investigators speculate that metformin may improve cognitive dysfunction by improving central insulin resistance in elderly obese patients.
A prospective, randomized controlled single center clinical cohort study will be conducted on 54 elderly obese patients with MCI. One group will receive metformin and lifestyle intervention, while the control group will receive simple lifestyle intervention. All subjects will be followed up for 26 weeks. Medical history collection, physical examination, and laboratory tests will be conducted before and after intervention, and the Montreal Cognitive Assessment Scale will be used for evaluation. Nasal insulin inhalation combined with fMRI will be used to evaluate central insulin resistance status as an objective basis for cognitive function evaluation. The main purpose of the study is to provide more accurate clinical research evidence for the prevention and treatment of MCI in elderly obese patients, in order to reduce the risk of developing dementia and alleviate the burden on families and society.
The prevalence of cognitive impairment among elderly obese patients is high, and early intervention for them is of great significance.
Cognitive impairment refers to the impairment of one or more aspects such as learning and memory, language, executive function, perceptual-motor function, complex attention, and social cognition, often accompanied by mental, behavioral, and personality abnormalities, including mild cognitive impairment (MCI) and dementia. Epidemiological studies have shown that the prevalence of MCI among people aged 60 and above in China is 15.5%, and the affected population reaches 38 million. Numerous studies have confirmed the clear association between obesity and cognitive impairment. The daily life of MCI patients is less interfered by cognitive deficits, but the proportion of their annual progression to dementia can reach 5-10%, which is much higher than the 1-2% incidence rate of the general population. 50% of MCI patients can develop dementia within 5 years and 20-30% of MCI patients can recover normal cognition. Therefore, early detection of MCI in elderly obese patients and timely intervention have important clinical significance and value.
Central nervous system insulin resistance plays a role in the pathogenesis of cognitive dysfunction. Functional magnetic resonance imaging(fMRI) can assess cognitive dysfunction by observing central insulin resistance.
Currently, the mechanisms of cognitive dysfunction in elderly obese patients include the pathological physiological effects of microvascular mechanisms and fat-derived factors. Insulin not only regulates peripheral metabolism but also acts on the central nervous system to regulate cognitive function. All cell types in the brain have an insulin signaling pathway, and studies have shown that brain insulin resistance can damage the plasticity of hippocampal synapses and memory function, thereby leading to cognitive decline. The evaluation of cognitive function is usually conducted using the Montreal Cognitive Assessment Scale(Moca), which includes multiple dimensions such as memory, attention, executive function, and language function, with a maximum score of 30. The score considered for diagnosing MCI is 20-26 (education> 10 years) or 20-25 (education≤ 10 years). However, in practical work, the collection of the scale is affected by many factors. fMRI can show changes in local blood flow and metabolic activities in the brain before brain structure changes, and can deeply understand brain functional changes, which is an important means for early diagnosis of cognitive dysfunction, efficacy monitoring, and mechanism research. By combining fMRI with nasal insulin inhalation, the response of different brain regions to insulin can be observed to assess the degree of central insulin resistance. If there is no neuroimaging or neurophysiological response after nasal insulin inhalation, it indicates the presence of central nervous system insulin resistance. Previous studies have shown that improving the state of central insulin resistance can delay or reverse cognitive decline. Therefore, the central insulin resistance state observed by fMRI can be used as an objective basis for evaluating cognitive function.
Metformin, as the first-line medication for type 2 diabetes, has been widely used. Basic research shows that metformin has the potential to activate the 5'AMP-activated protein kinase (AMPK) pathway, which plays a crucial role in the pathogenesis of dementia. Metformin can improve insulin resistance, reduce neuronal apoptosis, and reduce oxidative stress and inflammatory responses in the brain. Recent studies have shown that the use of metformin is associated with a significant reduction in the risk of dementia in elderly patients with type 2 diabetes. However, these studies were conducted on diabetes patients in large-scale databases, and drawing conclusions by comparing whether metformin was used or not would be affected by many interfering factors. Some earlier studies have shown that long-term use of metformin may even increase the risk of dementia. This may be related to vitamin B12 deficiency, the duration of metformin use, and the course of diabetes. Some small-sample short-term controlled studies have shown that in non-diabetic MCI patients, metformin can penetrate the blood-brain barrier and improve learning, memory, and attention. In conclusion, as a widely used traditional hypoglycemic drug, basic research suggests that metformin can improve central insulin resistance. Clinical studies in diabetes patients suggest a relatively definite possibility of improving cognitive impairment. However, there are currently few studies on the use of metformin to improve cognitive function in elderly overweight or obese patients with MCI.
Therefore, the investigators plan to conduct an intervention using an adequate dose of metformin in elderly overweight or obese patients with MCI, while using patients with simple lifestyle intervention as the control group. The investigators will use fMRI to evaluate the state of central insulin resistance as an objective basis for cognitive function assessment, reducing the limitations of cognitive scales and achieving early detection and intervention of cognitive impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group was administered metformin sustained-release tablets (taken once daily, 1500mg each time; if intolerable, the dosage was reduced to the maximum tolerated dose).
Drug: Metfomin
The intervention group is administered metformin sustained-release tablets (taken once daily, 1500mg each time; if intolerable, the dosage was reduced to the maximum tolerated dose).
fMRI
The insulin sensitivity of the central nervous system in the two groups of subjects before and after treatment is evaluated by nasal inhalation of insulin combined with fMRI.
Time frame: 26 weeks
Montreal Cognitive Assessment Scale (Moca scale)
The Moca scale score ranges from 0 to 30. The higher the score, the better the cognitive function. The Moca scale score for mild cognitive impairment ranges from 20 to 26 points (for those with more than 10 years of education) or 20 to 25 points (for those with 10 years or less of education). The investigators compare the scores of the Moca scale before and after the intervention.
Time frame: 26 weeks
body composition
The body composition is measured using Beijing Yueqi BIA. The indicators include weight (kg), skeletal muscle (kg), body fat (kg), body mass index (kg/m2), body fat percentage (%), visceral fat area (cm2), waist-to-hip ratio, and skeletal muscle index (kg/m2). The investigators compare the changes in body composition before and after the intervention.
Time frame: 26 weeks
grip strength
The grip strength is evaluated using an electronic grip strength tester. Each hand is tested twice, and the average values are taken. The side with the greater grip strength is selected as the final grip strength. A low grip strength is defined as less than 28 kg for men and less than 18 kg for women. The investigators compare the changes in grip strength before and after the intervention.
Time frame: 26 weeks
glycated hemoglobin
The glycated hemoglobin (%) is measured on an empty stomach, and the investigators compare the changes before and after the intervention.
Time frame: 26 weeks
insulin
The measurement of insulin (mIU/L) is conducted in the fasting state. The investigators compare the changes before and after the intervention.
Time frame: 26 weeks
C-peptide
The measurement of C-peptide (ng/ml) is conducted in the fasting state. The investigators compare the changes before and after the intervention.
Time frame: 26 weeks
blood glucose
The measurement of blood glucose (mmol/L) is conducted in the fasting state. The investigators compare the changes before and after the intervention.
Time frame: 26 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.
Of 25 phase 1/2 interventional studies under Cognitive Dysfunction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin